FDA publishes guidance on submission process for determining risk of investigational in vitro diagnostics

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Boca Raton resident Gabriela Sanchez recently found herself stepping into a mobile outreach vehicle operated by Sylvester Comprehensive Cancer Center.

April 17, 2026

Vol.52 No.15

By Claire Marie Porter

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

April 17, 2026

Vol.52 No.15

By Jacquelyn Cobb

Cancer History Project Editorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Most Favored Nation drug pricing could put China on top

China’s biotech sector is rapidly becoming a global innovation powerhouse. In oncology alone, Chinese licensing deals reached $30 billion in 2024—triple the United States’ output. Nearly a third of the world’s clinical trials now take place in China.

April 17, 2026

Vol.52 No.15

By John Stanford

Bridging communication and genomics: A path toward equitable cancer care

The era of genomic oncology is defined by complexity. Over the last decades, we have moved from single-gene tests to multi-gene panels and, eventually, will be routinely using whole-exome/whole-genome and transcriptome sequencing in clinical care.

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

Vol.52 No.15

By Jacquelyn Cobb

FDA publishes guidance on submission process for determining risk of investigational in vitro diagnostics

YOU MAY BE INTERESTED IN

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

Most Favored Nation drug pricing could put China on top

Bridging communication and genomics: A path toward equitable cancer care

FDA adds stereotactic breast biopsy needles to the shortage list

Renew today!

Subscriber content

Never miss an issue!

Login

FDA publishes guidance on submission process for determining risk of investigational in vitro diagnostics

YOU MAY BE INTERESTED IN

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0

Most Favored Nation drug pricing could put China on top

Bridging communication and genomics: A path toward equitable cancer care

FDA adds stereotactic breast biopsy needles to the shortage list

Never miss an issue!

Login

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0